William Blair Estimates DexCom’s Q1 Earnings (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at William Blair dropped their Q1 2025 earnings estimates for shares of DexCom in a report released on Monday, March 10th. William Blair analyst M. Andrew now anticipates that the medical device company will earn $0.33 per share for the quarter, down from their prior forecast of $0.34. The consensus estimate for DexCom’s current full-year earnings is $2.03 per share. William Blair also issued estimates for DexCom’s Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.59 EPS, Q4 2025 earnings at $0.64 EPS, Q1 2026 earnings at $0.44 EPS, Q2 2026 earnings at $0.58 EPS, Q3 2026 earnings at $0.69 EPS, Q4 2026 earnings at $0.72 EPS and FY2026 earnings at $2.43 EPS.

Several other brokerages have also commented on DXCM. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Citigroup increased their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Stock Down 3.2 %

Shares of NASDAQ DXCM opened at $68.48 on Wednesday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The firm has a market capitalization of $26.76 billion, a PE ratio of 47.89, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The firm has a fifty day simple moving average of $84.19 and a two-hundred day simple moving average of $76.87.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%.

Institutional Investors Weigh In On DexCom

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DXCM. Versant Capital Management Inc bought a new stake in DexCom during the 4th quarter worth approximately $25,000. Private Trust Co. NA raised its stake in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares during the period. Optiver Holding B.V. bought a new stake in DexCom during the 4th quarter worth approximately $33,000. TD Private Client Wealth LLC raised its stake in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after acquiring an additional 167 shares during the period. Finally, Larson Financial Group LLC raised its stake in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after acquiring an additional 137 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insider Activity

In related news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 45,083 shares of company stock valued at $3,826,604 in the last 90 days. 0.30% of the stock is currently owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.